Scholarlink

<p>Psilocybin is a rapid-acting antidepressant, but its mechanism of action in major depressive disorder remains unclear. In this secondary analysis of randomized, placebo-controlled trial with multimodal CSF and blood biomarker measurements, psilocybin selectively reduced CSF galanin and noradrenaline, implicating that normalization of these co-transmitters is a key pharmacodynamic signature.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月7日

查看全文
  • Wojciech Paslawski,
  • Daniel Doyon,
  • Carl Johan Ekman,
  • Hampus Yngwe,
  • Dejan Mamula,
  • Justyna Zareba-Paslawska,
  • Maria Beckman,
  • Zhi-Qing David Xu,
  • Tomas Hökfelt,
  • Mikael Tiger,
  • Johan Lundberg,
  • Per Svenningsson

摘要

Psilocybin is a rapid-acting antidepressant, but its mechanism of action in major depressive disorder remains unclear. In this secondary analysis of randomized, placebo-controlled trial with multimodal CSF and blood biomarker measurements, psilocybin selectively reduced CSF galanin and noradrenaline, implicating that normalization of these co-transmitters is a key pharmacodynamic signature.